share_log

Investors Bid BioLife Solutions (NASDAQ:BLFS) up US$53m Despite Increasing Losses YoY, Taking Five-year CAGR to 11%

Simply Wall St ·  Jan 8 20:08

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. Unfortunately for shareholders, while the BioLife Solutions, Inc. (NASDAQ:BLFS) share price is up 71% in the last five years, that's less than the market return. However, more recent buyers should be happy with the increase of 57% over the last year.

Since the stock has added US$53m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

Given that BioLife Solutions didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In the last 5 years BioLife Solutions saw its revenue grow at 29% per year. That's well above most pre-profit companies. It's nice to see shareholders have made a profit, but the gain of 11% over the period isn't that impressive compared to the overall market. You could argue the market is still pretty skeptical, given the growing revenues. Arguably this falls in a potential sweet spot - modest share price gains but good top line growth over the long term justifies investigation, in our book.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

big
NasdaqCM:BLFS Earnings and Revenue Growth January 8th 2025

Take a more thorough look at BioLife Solutions' financial health with this free report on its balance sheet.

A Different Perspective

We're pleased to report that BioLife Solutions shareholders have received a total shareholder return of 57% over one year. That gain is better than the annual TSR over five years, which is 11%. Therefore it seems like sentiment around the company has been positive lately. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that BioLife Solutions is showing 1 warning sign in our investment analysis , you should know about...

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment